175 related articles for article (PubMed ID: 12435691)
1. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
[TBL] [Abstract][Full Text] [Related]
2. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
3. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
5. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
[TBL] [Abstract][Full Text] [Related]
7. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Kosel BW; Aweeka FT; Benowitz NL; Shade SB; Hilton JF; Lizak PS; Abrams DI
AIDS; 2002 Mar; 16(4):543-50. PubMed ID: 11872997
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Acosta EP; Wu H; Hammer SM; Yu S; Kuritzkes DR; Walawander A; Eron JJ; Fichtenbaum CJ; Pettinelli C; Neath D; Ferguson E; Saah AJ; Gerber JG;
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1358-66. PubMed ID: 15483465
[TBL] [Abstract][Full Text] [Related]
9. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
[TBL] [Abstract][Full Text] [Related]
10. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
[TBL] [Abstract][Full Text] [Related]
13. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Raines CP; Flexner C; Sun E; Heath-Chiozzi M; Lewis RH; Fields C; Deetz C; Apuzzo L; Eshleman SH; Jackson JB; Gallant JE
J Acquir Immune Defic Syndr; 2000 Dec; 25(4):322-8. PubMed ID: 11114832
[TBL] [Abstract][Full Text] [Related]
15. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
[TBL] [Abstract][Full Text] [Related]
16. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Skowron G; Leoung G; Hall DB; Robinson P; Lewis R; Grosso R; Jacobs M; Kerr B; MacGregor T; Stevens M; Fisher A; Odgen R; Yen-Lieberman B
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):351-8. PubMed ID: 15097151
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
Pfister M; Labbé L; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Antimicrob Agents Chemother; 2003 Jan; 47(1):130-7. PubMed ID: 12499180
[TBL] [Abstract][Full Text] [Related]
19. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
[TBL] [Abstract][Full Text] [Related]
20. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
